Clinical trials
Treatment clinical trials
Below are recruiting treatment clinical trials, each written for real people, not researchers. We’re tracking 8,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07499544RecruitingPhase 3
Testing Libevitug for chronic hepatitis D
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
Garden Grove, CaliforniaAges 12–70 - NCT06762782RecruitingPhase 2
Lenvatinib after liver cancer surgery to prevent recurrence
This trial tests whether taking lenvatinib after liver cancer surgery can lower the chance of the cancer coming back. It is for people who have a high risk of recurrence and have recently had their liver tumor completely removed.
Nanjing, JiangsuAges 18–80 - NCT07506499Recruiting
Cardiac Rehab for Hospitalized Heart Failure Patients
This study tests whether a cardiac rehabilitation program (a supervised exercise and education plan) helps people recovering in the hospital from severe heart failure. It is for those aged 45–65 whose heart pumps less than 40% of its normal amount.
Banī Suwayf, Beni-Suef GovernorateAges 45–65 - NCT07503652RecruitingPhase 4
Xeligekimab for moderate to severe palmoplantar pustulosis
This study tests a new drug (Xeligekimab) for people with moderate to severe palmoplantar pustulosis — a condition causing painful blisters on the hands and feet. It may be an option if other treatments haven't worked well.
ShenyangAges 18–75 - NCT07506902Recruiting
Daily adjusted radiation for head and neck cancer
This trial tests a newer, more precise way of giving daily radiation for head and neck cancer. The treatment plan is adjusted each day to better target the tumor and protect healthy tissue.
CopenhagenAges 18 years+ - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT07506018Recruiting
MucoLock for mouth pain caused by stomatitis
This study tests a new mouth rinse, MucoLock, to see if it can help people with severe mouth pain (stomatitis). If you have burning or painful mouth sores that rate very high on a pain scale, this trial may offer a new treatment option.
Miami, FloridaAges 18 years+ - NCT07505199RecruitingPhase 1
Immune cell therapy for advanced heart failure from blocked arteries
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07499284Recruiting
Haplo-Cord Stem Cell Transplant for Aplastic Anemia
This trial tests a new way of using a mix of donor stem cells (from a half-matched family member and a cord blood unit) to treat aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal is to see if this transplant approach is safe and helps rebuild healthy blood cells.
Suzhou, JiangsuAges 14 years+ - NCT07501897Recruiting
Cold plasma for healing cannula wounds in ECLS patients
This trial tests whether cold atmospheric plasma—a gentle, gas-based treatment—can help heal wounds where tubes enter the body for life support. It might offer a new way to care for these delicate spots.
TaipeiAges 18 years+ - NCT07499596Recruiting
Black Mulberry Mouthwash for Gum Inflammation
This trial tests whether a mouthwash made from black mulberry (Morus nigra) can help treat gingivitis (gum inflammation). If you have gum disease but not advanced gum disease, you may be able to join for about 2 weeks of using the mouthwash along with regular brushing.
Battalgazi, MalatyaAges 18–65 - NCT07499271RecruitingPhase 2
Targeted therapy for newly diagnosed DLBCL with TP53 mutation
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
Suzhou, JiangsuAges 18–70 - NCT07499219Enrolling by invitation
Digital help for students waiting for mental health support
This study tests a short digital program for students who are on a waiting list for psychological treatment. It aims to see if the program can provide support while they wait.
Oslo, OsloAges 18–80 - NCT07498907RecruitingPhase 3
Disitamab vedotin plus radiation for high-risk bladder cancer in kidney tube
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
BeijingAges 18 years+ - NCT07504991Recruiting
Radiofrequency and ultrasound for pain after childbirth
This trial tests whether combining radiofrequency with ultrasound can reduce pain during sex after having a baby. It may help women who have had moderate to severe pain for a while after a vaginal delivery.
Tarragona, TARRAGONAAges 18–50 - NCT07503301Enrolling by invitation
Study on stroke recovery and limb therapy
This trial tests if a limb therapy called RIC can help people recover from a stroke caused by small vessel disease. It is designed for people aged 50-65 who have had a recent stroke and have few other health issues.
Hangzhou, ZhejiangAges 50–65 - NCT07501533RecruitingPhase 2
Insulin timing for severe stroke patients with high blood sugar
This study compares giving insulin early versus waiting a bit to lower blood sugar after a severe stroke. It may help understand the best timing to treat high blood sugar in this situation.
Wuhu, AnhuiAges 18 years+ - NCT04615143RecruitingPhase 2
Tislelizumab with or without lenvatinib before liver surgery
This trial studies whether taking tislelizumab alone or with lenvatinib before surgery can shrink recurrent liver cancer and improve outcomes. It may help by treating the cancer earlier (before the tumor is removed).
Guangzhou, GuangdongAges 18–75 - NCT06386874Recruiting
Magnetic field therapy for arm recovery after stroke
This study tests a new magnetic device applied to the head to help improve arm function after a stroke. You will use the device while doing exercises, and a caregiver will support you with a mobile app and video calls.
Downey, CaliforniaAges 22–80 - NCT06503692Recruiting
Comparing balloons for dialysis graft narrowing
This trial tests two types of balloon catheters (scoring and high-pressure) to open up narrowed spots in dialysis grafts. The goal is to find which works better to keep your access working well for dialysis.
Beijing, Beijing MunicipalityAges 18–80 - NCT05353348Recruiting
Program to treat mild anemia around heart surgery
This trial tests a combined treatment plan to improve anemia (low blood count/iron levels) before and around the time of major elective heart surgery. It may help reduce the need for blood transfusions and support safer recovery.
Hangzhou, ZhejiangAges 18 years+ - NCT06664021RecruitingPhase 2
Tislelizumab and S-1 for recurrent high-risk bile duct cancer
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
Fuyang, AnhuiAges 18–75 - NCT07493538RecruitingPhase 2
Blood stem cell transplant with lower-intensity chemo for blood cancers
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Minneapolis, MinnesotaAges 2–75 - NCT07491016Recruiting
Telitacicept plus baricitinib for hard-to-treat rheumatoid arthritis
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
Hangzhou, ZhejiangAges 18–85
Hear when a new Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for treatment?
- Yes. Clin2 currently lists 8,322 recruiting treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.